Regeneron Pharmaceuticals News

Kurse + Charts + Realtime	News + Analysen	Fundamental	Unternehmen	zugeh. Wertpapiere	Aktion
Kurs + Chart	Chart (gross)	News + Adhoc	Bilanz/GuV	Termine	Strukturierte Produkte	Portfolio
Times + Sales	Chartvergleich	Analysen	Schätzungen	Profil	Trading-Depot	Watchlist
Börsenplätze	Realtime Push	Kursziele	Dividende/GV
Historisch			Analysen

Kurse + Charts + Realtime

News + Analysen

Fundamental

Unternehmen

zugeh. Wertpapiere

Aktion

Kurs + Chart

Chart (gross)

News + Adhoc

Bilanz/GuV

Termine

Strukturierte Produkte

Portfolio

Times + Sales

Chartvergleich

Analysen

Schätzungen

Profil

Trading-Depot

Watchlist

Börsenplätze

Realtime Push

Kursziele

Dividende/GV

Historisch

Analysen

07.01.19	Regeneron, Sanofi Select Two Clinical-stage Antibodies For Ongoing Collaboration (RTTNews)
04.01.19	Regeneron Posting Strong Gain On Upgrade By Guggenheim (RTTNews)
06.11.18	Sanofi kommt US-Zulassung von Hautmedikament Dupixent für Jugendliche näher (AWP) Der Pharmakonzern Sanofi kommt bei der Zulassung seines Mittels Dupixent gegen Hautkrankheiten für Jugendliche voran.» mehr
06.11.18	Regeneron Pharmaceuticals Q3 adjusted earnings Beat Estimates (RTTNews)
06.11.18	Regeneron : FDA Grants Priority Review For Dupixent (RTTNews)
04.11.18	Ausblick: Regeneron Pharmaceuticals verkündet Quartalsergebnis zum jüngsten Jahresviertel (finanzen.net)
25.10.18	Regeneron: Eylea Phase 3 Panorama Trial Meets Primary, Secondary Endpoints (RTTNews)
22.10.18	Regeneron Pharma: FDA Approves Asthma Indication For Dupixent - Quick Facts (RTTNews)
22.10.18	FDA Extends Date On BMY's SBLA, Genmab Meets Phase 3 Goals, NCNA, LPTX On Watch (RTTNews)
20.10.18	FDA genehmigt Dupixent von Sanofi als Asthma-Therapie (Dow Jones) Das Neurodermitis-Medikament Dupixent von Regeneron und Sanofi kann in den USA künftig auch zur Behandlung von Asthma eingesetzt werden.» mehr
16.10.18	Regeneron : Dupixent Shows Positive Results In Two Phase 3 Trials On CRSwNP (RTTNews)
28.09.18	Biotech Stocks Facing FDA Decision In October (RTTNews)
13.09.18	ADIL On Track, PGNX Slumps On Phase III Study Failure, VNDA On Watch (RTTNews)
12.09.18	Sanofi And Regeneron : FDA To Review SBLA For Praluent Injection (RTTNews)
12.09.18	FOMX Soars On Acne Trial Data, GLPG Abuzz, ACRX To Face FDA Panel In Oct. (RTTNews)
19.08.18	Week Ahead In Pharmaceuticals: 7 Stocks To Watch (TNXP, REGN, KALA...) (RTTNews)
17.08.18	Regeneron Pharma: FDA Okays EYLEA Injection SBLA In Wet AMD (RTTNews)
16.08.18	Teva And Regeneron Announce Positive Phase 3 Fasinumab Results (RTTNews)
14.08.18	MBIO & Bubble Boy Disease Gene Therapy, Busy Months Ahead For EIGR, UMRX (RTTNews)
13.08.18	Regeneron Pharma: FDA Issues Response Letter On SBLA For EYLEA - Quick Facts (RTTNews)
11.08.18	Week Ahead In Pharmaceuticals: 5 Stocks To Watch (REGN, PFE, ALT...) (RTTNews)
06.08.18	Regeneron, Bluebird Bio Announce Collaboration - Quick Facts (RTTNews)
04.08.18	Week Ahead In Pharmaceuticals - 10 Stocks To Watch (ALNY, INSM, PRTK...) (RTTNews)
02.08.18	Regeneron Showing Strong Move To The Upside (RTTNews)
02.08.18	Regeneron Pharmaceuticals Q2 adjusted earnings Beat Estimates (RTTNews)
26.07.18	Biotech Stocks Facing FDA Decision In August (RTTNews)
06.06.18	Regeneron, Zoetis Announce Research Collaboration - Quick Facts (RTTNews)
06.06.18	Regeneron and Zoetis Announce Collaboration to Research Antibody Therapies for Use in Animal Health (PR Newswire)
04.06.18	New England Journal of Medicine publishes pivotal cemiplimab trials showing positive results in advanced cutaneous squamous cell carcinoma (PR Newswire)
04.06.18	New England Journal of Medicine Publishes Pivotal Cemiplimab Trials Showing Positive Results in Advanced Cutaneous Squamous Cell Carcinoma (PR Newswire)
31.05.18	Regeneron's Investigational Ebola Treatment Shipping to Democratic Republic of the Congo for Use in Current Outbreak (PR Newswire)
21.05.18	New England Journal of Medicine publishes two positive Phase 3 trials showing Dupixent® (dupilumab) improved moderate-to-severe asthma (PR Newswire)
21.05.18	New England Journal of Medicine Publishes Two Positive Phase 3 Trials Showing DUPIXENT® (dupilumab) Improved Moderate-to-Severe Asthma (PR Newswire)
18.05.18	Regeneron Announces Upcoming Investor Conference Presentation (PR Newswire)
16.05.18	Regeneron and Sanofi Share First Positive Clinical Data for Cemiplimab in Advanced Non-small Cell Lung Cancer at ASCO (PR Newswire)
16.05.18	Dupixent® (dupilumab) showed positive Phase 3 results in adolescents with inadequately controlled moderate-to-severe atopic dermatitis (PR Newswire)
16.05.18	Regeneron, Sanofi: Phase 3 Dupixent Trial Meets Primary, Key Secondary Endpoints (RTTNews)
16.05.18	Positive Phase 3 Trial of DUPIXENT® (dupilumab) in Adolescents with Inadequately Controlled Moderate-to-severe Atopic Dermatitis (PR Newswire)
03.05.18	Regeneron Pharmaceuticals Q1 adjusted earnings Beat Estimates (RTTNews)
03.05.18	Regeneron Reports First Quarter 2018 Financial and Operating Results (PR Newswire)
02.05.18	DocPanel Announces Partnership with the University of Southern California Keck School of Medicine (PR Newswire)
01.05.18	2018 Global Channel Report Reveals Clients Attacked Mostly Through Privileged Accounts (PR Newswire)
01.05.18	Sanofi, Renegeron To Lower Net Price Of Praluent Injection - Quick Facts (RTTNews)
01.05.18	Sanofi and Regeneron to lower net price of Praluent® (alirocumab) Injection in exchange for straightforward, more affordable patient access for Express Scripts patients (PR Newswire)
01.05.18	Regeneron and Sanofi to Lower Net Price of Praluent® (alirocumab) Injection in Exchange for Straightforward, More Affordable Patient Access for Express Scripts Patients (PR Newswire)
01.05.18	INGN Soars On Revised Outlook, MRK Faces FDA In Sep., KPTI Taken By STORM (RTTNews)
30.04.18	Regeneron And Sanofi Say FDA Accepts Priority Review BLA For Cemiplimab (RTTNews)
30.04.18	FDA to Conduct Priority Review of Cemiplimab as a Potential Treatment for Advanced Cutaneous Squamous Cell Carcinoma (PR Newswire)
30.04.18	FDA to Conduct Priority Review of Cemiplimab as a Potential Treatment for Advanced Cutaneous Squamous Cell Carcinoma (PR Newswire)
23.04.18	Regeneron Announces Upcoming Investor Conference Presentations (PR Newswire)

Aktien Top/Flop

SMI
SPI
SLI
SMIM
DAX
ESTOXX
Dow Jones
S&P 500
NASDAQ 100
Nikkei 225

Sika	226.40	2.30 %	K V
Holcim	97.22	1.50 %	K V
Roche Hldg G	263.60	1.38 %	K V
Novartis	92.79	1.35 %	K V
ABB	48.01	1.01 %	K V
Zurich Insur Gr	584.40	-0.34 %	K V
CieFinRichemont	164.45	-0.69 %	K V
Part Grp Hldg	1’167.00	-0.77 %	K V
Lonza Grp	568.20	-1.04 %	K V
UBS Group	27.25	-2.71 %	K V

mehr

01.04.25		Zuversicht in New York: NASDAQ 100 zum Ende des Dienstagshandels mit positivem Vorzeichen
25.03.25		Aufschläge in New York: NASDAQ 100 notiert schlussendlich im Plus
25.03.25		Börse New York: S&P 500 beendet die Sitzung im Plus
25.03.25		Freundlicher Handel in New York: NASDAQ 100-Anleger greifen nachmittags zu
14.03.25		Optimismus in New York: NASDAQ 100 zum Handelsende mit Gewinnen
14.03.25		Aufschläge in New York: NASDAQ 100 nachmittags in Grün
14.03.25		Freitagshandel in New York: S&P 500 nachmittags stärker
14.03.25		Aufschläge in New York: S&P 500 mit grünem Vorzeichen

01.04.25

Zuversicht in New York: NASDAQ 100 zum Ende des Dienstagshandels mit positivem Vorzeichen

25.03.25

Aufschläge in New York: NASDAQ 100 notiert schlussendlich im Plus

25.03.25

Börse New York: S&P 500 beendet die Sitzung im Plus

25.03.25

Freundlicher Handel in New York: NASDAQ 100-Anleger greifen nachmittags zu

14.03.25

Optimismus in New York: NASDAQ 100 zum Handelsende mit Gewinnen

14.03.25

Aufschläge in New York: NASDAQ 100 nachmittags in Grün